In this issue of Blood, Gebhart et al report a prospective observational cohort study evaluating 151 patients with persistently positive lupus anticoagulant (LA) for a median period of 8.2 years. They observed increased mortality in LA-positive patients, mainly due to new thrombotic events.
Keyphrases
- systemic lupus erythematosus
- end stage renal disease
- atrial fibrillation
- venous thromboembolism
- disease activity
- ejection fraction
- newly diagnosed
- peritoneal dialysis
- prognostic factors
- pulmonary embolism
- type diabetes
- cardiovascular events
- risk factors
- rheumatoid arthritis
- patient reported outcomes
- cardiovascular disease